The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Clovis Oncology, Inc. | Common Stock | 189464100 | 1,514,584 | 101,855 | SH | OTR | 0 | 101,855 | 0 | ||
CymaBay Therapeutics, Inc. | Common Stock | 23257D103 | 3,893,270 | 543,753 | SH | OTR | 0 | 543,753 | 0 | ||
Gritstone Oncology, Inc. | Common Stock | 39868T105 | 34,566,629 | 3,102,929 | SH | OTR | 0 | 3,102,929 | 0 | ||
Second Sight Medical Products, Inc. | Common Stock | 81362J100 | 3,597,974 | 4,492,975 | SH | OTR | 0 | 4,492,975 | 0 | ||
Ocular Therapeutix, Inc. | Common Stock | 67576A100 | 9,747,690 | 2,215,384 | SH | OTR | 0 | 2,215,384 | 0 | ||
Audentes Therapeutics, Inc. | Common Stock | 05070R104 | 20,971,260 | 553,916 | SH | OTR | 0 | 553,916 | 0 | ||
CRISPR Therapeutics AG | Common Stock | H17182108 | 200,122,625 | 4,248,888 | SH | OTR | 0 | 4,248,888 | 0 | ||
OpGen, Inc. | Common Stock | 68373L109 | 40,121 | 102,167 | SH | OTR | 0 | 102,167 | 0 | ||
Veracyte, Inc. | Common Stock | 92337F107 | 68,732,336 | 2,410,815 | SH | OTR | 0 | 2,410,815 | 0 |